FDA.reportPublic FDA data

16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi]

RxCUI
2700745
RxNorm name
16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi]
Display name
16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi]
Full name
16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:12

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761198Avzivibevacizumab-tnjn351(k) BiosimilarRx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
a3976cf9-9edb-4ca2-9375-9bcd2e32f5b4Avzivi 400 MG in 16 ML Injection [PSN] · 16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi] [SBD] · 16 ML Avzivi 25 MG/ML Injection [SY] · Avzivi 400 MG per 16 ML Injection [SY]44These highlights do not include all the information needed to use Avzivi safely and effectively. See full prescribing information for Avzivi. Avzivi ® (bevacizumab-tnjn) injection, for intravenous use Initial U.S. Approval: 2023 Avzivi (bevacizumab-tnjn) is biosimilar to AVASTIN ® (bevacizumab)20250930